Federal Register / Vol. 74, No. 187 / Tuesday, September 29, 2009 / Notices 49879 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Immunology 

Integrated Review Group, Innate Immunity 

and Inflammation Study Section. 

Date: October 15–16, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Key Bridge Marriott, 1401 Lee 

Highway, Arlington, VA 22209. 

Contact Person: Tina McIntyre, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4202, 

MSC 7812, Bethesda, MD 20892, 301–594– 

6375, mcintyrt@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict. 

Date: October 15, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Jose Fernando Arena, PhD, 

MD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3135, 

MSC 7770, Bethesda, MD 20892, 301–435– 

1735, arenaj@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Microcirculation, Hypertension and 

Atherosclerosis. 

Date: October 20–21, 2009. 

Time: 11 a.m. to 9 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Anshumali Chaudhari, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4124, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1210, chaudhaa@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Investigations on Primary Immunodeficiency 

Diseases. 

Date: October 20, 2009. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Jin Huang, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4095G, MSC 7812, Bethesda, 

MD 20892, 301–435–1230, jh377p@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Eukaryotic 

Pathogens and Their Vectors. 

Date: October 20, 2009. 

Time: 3:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call) 

Contact Person: Richard G. Kostriken, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3192, 

MSC, 7808 Bethesda, MD 20892, 301–402– 

4454, kostrikr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PARO8– 

224: System Dynamics Methodologies. 

Date: October 26, 2009. 

Time: 11 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Fungai Chanetsa, MPH, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3135, 

MSC 7770, Bethesda, MD 20892, 301–435– 

1262, fungai.chanetsa@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Cell Death and Neurodegeneration. 

Date: October 26, 2009. 

Time: 12 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call) 

Contact Person: Alexander Yakovlev, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5206, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1254, yakovleva@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 22, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23336 Filed 9–28–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Reproductive Sciences and Development. 

Date: October 14–15, 2009. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

Applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Krish Krishnan, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6164, 

MSC 7892, Bethesda, MD 20892, (301) 435– 

1041, krishnak@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Mental 

Health and Neurodegenerative Disorders 

Members. Conflict. 

Date: October 26–27, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Suzan Nadi, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 521 7B, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1259, nadis@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts: Hepatobiliary Pathophysiology, 

Toxicology and Pharmacology. 

Date: October 26–27, 2009. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

Applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting) 

Contact Person: Bonnie L. Burgess-Beusse, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1783, beusseb@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Ethical, 

Legal and Societal Implications of Genetics. 

Date: October 29, 2009. 

Time: 2 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

Applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call) 

Contact Person: Diane L. Stassi, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2200, 


jlentini on DSKJ8SOYB1PROD with NOTICES
49880 Federal Register / Vol. 74, No. 187 / Tuesday, September 29, 2009 / Notices 

MSC 7890, Bethesda, MD 20892, 301–435– 

2514, stassid@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 21, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23240 Filed 9–28–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0443] 

Anti-Infective Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Anti-Infective Drugs 

Advisory Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on October 26, 2009, from 8:30 a.m. to 4 p.m. 

Addresses: Electronic comments should be 

submitted to http://www.regulations.gov. 

Enter ‘‘FDA–2009–N–0443’’ and follow the 

prompts to submit your statement. Written 

comments should be submitted to the 

Division of Dockets Management (HFA-305), 

Food and Drug Administration, 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. All 

comments received will be posted without 

change, including any personal information 

provided. Comments received on or before 

October 5, 2009, will be provided to the 

committee before the meeting. 

Location: Hilton Washington DC/Silver 

Spring, The Ballrooms, 8727 Colesville Rd., 

Silver Spring, MD. The hotel phone number 

is 301–589–5200. 

Contact Person: Minh Doan, Center for 

Drug Evaluation and Research (HFD–21), 

Food and Drug Administration, 5600 Fishers 

Lane (for express delivery, 5630 Fishers 

Lane, rm. 1093), Rockville, MD 20857, 301– 

827–7001, FAX: 301–827–6776, e-mail: 

Minh.Doan@fda.hhs.gov, or FDA Advisory 

Committee Information Line, 1–800–741– 

8138 (301–443–0572 in the Washington DC 

area), code 3014512530. Please call the 

Information Line for up-to-date information 

on this meeting. A notice in the Federal 

Register about last minute modifications that 

impact a previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide timely 

notice. Therefore, you should always check 

the agency’s Web site and call the 

appropriate advisory committee hot line/ 

phone line to learn about possible 

modifications before coming to the meeting. 

Agenda: The committee will discuss 

updating susceptibility test information in 

systemic antibacterial drug product labeling. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http://

www.fda.gov/AdvisoryCommittees/Calendar/

default.htm. Scroll down to the appropriate 

advisory committee link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before 

October 16, 2009. Oral presentations from the 

public will be scheduled between 

approximately 12:45 p.m. and 1:45 p.m. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of the 

general nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and an 

indication of the approximate time requested 

to make their presentation on or before 

October 9, 2009. Time allotted for each 

presentation may be limited. If the number of 

registrants requesting to speak is greater than 

can be reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by October 12, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Minh Doan 

at least 7 days in advance of the meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/

AdvisoryCommittees/AboutAdvisory

Committees/ucm111462.htm for procedures 

on public conduct during advisory 

committee meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: 9/23/09. 

David Horowitz, 

Assistant Commissioner for Policy 

[FR Doc. E9–23437 Filed 9–28–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Blood Products Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Blood Products 

Advisory Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on November 16, 2009, from 8 a.m. to 5:30 

p.m. and on November 17, 2009, from 8 a.m. 

to 5 p.m. 

Location: Bethesda Marriott Hotel, 5151 

Pooks Hill Rd., Bethesda, MD 20814. 

Contact Person: William Freas or Pearline 

K. Muckelvene, Center for Biologics 

Evaluation and Research (CBER), Food and 

Drug Administration, 1401 Rockville Pike 

(HFM–71), Rockville, MD 20852, 301–827– 

0314, or FDA Advisory Committee 

Information Line, 1–800–741–8138 (301– 

443–0572 in the Washington, DC area), code 

3014519516. Please call the Information Line 

for up-to-date information on this meeting. A 

notice in the Federal Register about last 

minute modifications that impact a 

previously announced advisory committee 

meeting cannot always be published quickly 

enough to provide timely notice. Therefore, 

you should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn about 

possible modifications before coming to the 

meeting. 

Agenda: On November 16, 2009, in the 

morning the Committee will hear updates on 

the following topics: the HHS Advisory 

Committee on Blood Safety and Availability, 

Dengue virus outbreak, and 2009 A/H1N1 

Pandemic and the impact on blood safety and 

availability. The Committee will then discuss 

blood donor deferral for malaria risk 

associated with travel to Mexico. In the 

afternoon the Committee will discuss the 

design of a new phase III study of pathogen 

inactivation of human platelets using the 

Cerus, INTERCEPT Blood System. On 

November 17, 2009, in the morning the 

Committee will discuss blood pressure and 

pulse as blood donor eligibility criteria, and 

in the afternoon the committee will discuss 

the public health need and performance 

characteristics of over-the-counter home-use 

HIV test kits. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 


jlentini on DSKJ8SOYB1PROD with NOTICES